Neutral
Johnson & Johnson's stock remains steady amid Kenvue stake sale and pharma growth.
In the past 24 hours, Johnson & Johnson's stock has maintained stability, reflecting the company's ongoing transition following the 2023 Kenvue consumer-health separation. The latest quarterly results highlight mid-single-digit revenue growth and resilient margins, driven by expanding pharmaceutical and medtech operations.
Key points
- Johnson & Johnson's stock holds steady as Kenvue stake sale and pharma growth reshape the group.
Sources
AI-generated from public news sources. Not financial advice.
